Nicole R. Hadas - Feb 27, 2024 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Signature
/s/ Carolyn Rucci, attorney-in-fact for Nicole R. Hadas
Stock symbol
AKBA
Transactions as of
Feb 27, 2024
Transactions value $
-$11,265
Form type
4
Date filed
2/29/2024, 06:03 PM
Previous filing
Feb 2, 2024
Next filing
Mar 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Sale -$11.3K -7.41K -1.1% $1.52 669K Feb 27, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
F2 This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.